Vimarsana
Biggest News Aggregation in the World

Page 2 - Nir Hacohen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nir Hacohen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nir Hacohen Today - Breaking & Trending Today

Boosting the body's anti-viral immune respons - Vimarsana News

Boosting the body's anti-viral immune respons

Aging cells express a protein that is produced by human cytomegalovirus and is targeted by certain immune cells in the body. Harnessing the immune response to this protein could have multiple health benefits during aging.

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2022 YOUNG INVESTIGATOR AWARDS TOTALING $7.2 MILLION FOR PROSTATE CANCER RESEARCH - Vimarsana News

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2022 YOUNG INVESTIGATOR AWARDS TOTALING $7.2 MILLION FOR PROSTATE CANCER RESEARCH

/PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the Class of 2022 Young Investigator Award recipients totaling $7.2 million in funding for...

Mass General Hospital Gets Funding to Sequence Rare Melanoma Subtypes, Hunt for Novel Drug Targets - Vimarsana News

Mass General Hospital Gets Funding to Sequence Rare Melanoma Subtypes, Hunt for Novel Drug Targets

The research is focused on mucosal and acral melanomas, tumors that don't have the molecular features that allow cutaneous melanoma patients to respond to targeted drugs.

Melanoma Monday: 2022 Immunotherapy Research Updates - Vimarsana News

Melanoma Monday: 2022 Immunotherapy Research Updates

Melanoma is, sadly, a cancer that is on the rise. The number of Americans diagnosed annually has increased by over 30 percent in the past decade. However, recent advances in science may give hope to patients with melanoma and their families. In April, CRI CLIP Investigator Nir Hacohen, Ph.D.

Why some die, some survive when equally ill from COVID-19 - INDIA New England News - Vimarsana News

Why some die, some survive when equally ill from COVID-19 - INDIA New England News

Why some die, some survive when equally ill from COVID-19 The Harvard Gazette Researchers at Harvard-affiliated Massachusetts General Hospital (MGH) have identified the protein “signature” of severe COVID-19, which they describe in a new study published in Cell Reports Medicine. “We were interested in asking whether we could identify mechanisms that might be contributing to death in COVID-19,” says MGH infectious disease expert Marcia Goldberg, who studies interactions between microbial pathogens and their hosts, and is senior author of the study. “In other words, why do some patien...